Authorization to initiate phase 3 confirmatory study in mastocytosis
24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
Update on masitinib programs timelines
10/10/2019 – AB Science provides update on masitinib programs timelines
First half of 2019 results
30/09/2019 – AB Science reports its revenues for the first half of 2019
10M€ raised through a private placement
19/08/2019 – AB Science announces the success of a private placement
AB Science to present at two upcoming conferences in September 2019
12/08/2019 – AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York.
Update on masitinib clinical program
05/08/2019 – AB Science provides an update on its masitinib clinical program.
Results of masitinib study in metastatic melanoma
02/08/2019 – AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma.
AB Science Corporate Presentation
22/07/2019 – AB Science Corporate Presentation – July 2019
Summary of the webconference held on July 8, 2019
09/07/2019 – AB Science is providing a summary of the web conference held on July 8, 2019
July 8 2019 web conference presentation
08/07/2019 – AB Science web conference presentation